Alogliptin
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo- 3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile |
|
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
| Identifiers | |
| CAS number | 850649-62-6 |
| ATC code | A10BH04 |
| PubChem | CID 11450633 |
| ChemSpider | 9625485  |
| UNII | JHC049LO86 |
| KEGG | D06553 |
| ChEMBL | CHEMBL376359 |
| Chemical data | |
| Formula | C18H21N5O2 |
| Mol. mass | 339.39 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Alogliptin (codenamed SYR-322) is an investigational anti-diabetic drug in the DPP-4 inhibitor class,[1] being developed by Takeda Pharmaceutical Company. In January 2008, Takeda submitted a New Drug Application for alogliptin to the U.S. Food and Drug Administration, after positive results from Phase III clinical trials.[2] However, the FDA submission was suspended or withdrawn in June 2009 needing more data.[3]
[edit] References
- ^ Feng J, Zhang Z, Wallace MB, et al. (2007). "Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV". J. Med. Chem. 50 (10): 2297–300. doi:10.1021/jm070104l. PMID 17441705.
- ^ "Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S." (Press release). Takeda Pharmaceutical Company. January 4, 2008. http://www.takeda.com/press/article_28864.html. Retrieved 2008-01-09.
- ^ "GEN News Highlights: Takeda Pulls MAA for Type 2 Diabetes Therapy". Genetic Engineering and Biotechnology News. 4 June 2009. http://www.genengnews.com/news/bnitem.aspx?name=55661199&source=genwire.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
